Skip to main content
Premium Trial:

Request an Annual Quote

UCSF Will Use atugen Technology in Epithelial Membrane Research

NEW YORK, Jan. 23 - A biochemist at the University of California at San Francisco will use atugen's gene-expression-blocking technology to study the functioning of epithelial membrane.

 

Under the agreement, atugen USA, a division of the German-based concern, will develop antisense reagents in order to block genes associated with epithelial membrane regulation in the canine kidney. The functional genomics company retains the option to commercialize technology resulting from this arrangement.

 

Financial details were not disclosed.

 

The biochemist, Keith Mostov, studies the way that individual cells aggregate to form multicellular epithelial tissue, a line of research that may ultimately be relevant in the treatment of cancer and other epithelial diseases.

 

This is atugen's first significant collaboration with an academic researcher, and the company's senior director for business development said in a statement that atugen intends to establish others.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.